NASDAQ:CLVS
Delisted
Clovis Oncology Stock News
$0.151
+0 (+0%)
At Close: Apr 19, 2023
Why Clovis Oncology Stock Was Plummeting This Week
07:12am, Friday, 06'th May 2022
Investors bailed from the company after a quarterly results and operational update.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
02:22pm, Thursday, 05'th May 2022 Zacks Investment Research
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
06:21pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
03:48pm, Wednesday, 04'th May 2022
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2022 Results - Earnings Call Transcript
12:30pm, Wednesday, 04'th May 2022
Clovis Oncology, Inc. (NASDAQ:CLVS ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR and Corporate Communications Patrick Mahaffy - President and CEO
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
05:00pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
04:10pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
12:35pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
04:21pm, Monday, 02'nd May 2022 Zacks Investment Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
03:10pm, Monday, 02'nd May 2022 Zacks Investment Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
02:01pm, Monday, 02'nd May 2022 Zacks Investment Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis: Shifting Toward Nuclear Medicine
12:33pm, Monday, 25'th Apr 2022
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trad
Why Clovis Oncology Stock Fell 10.5% on Monday
08:51pm, Monday, 18'th Apr 2022 The Motley Fool
Clovis' shares dropped early in the day then rallied.
